ArticleFrontiers in medicine2025
Acute kidney injury after myocardial infarction: prognostic implications via dual robust methods.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Emerging Prognostic Risk Factors in Acute Coronary Syndromes: Beyond Traditional Risk Assessment.Journal of clinical medicine · 2026Review
- Prognostic Value of the Osaka Prognostic Score for One-Year Mortality in Patients with ST-Segment Elevation Myocardial Infarction: A Retrospective Observational Cohort Study.Journal of clinical medicine · 2026Article
- Incidence and risk factors of acute kidney injury after myocardial infarction; a prospective cohort study with impact of timing of presentation on other risk factors.BMC nephrology · 2026Article
- Machine learning-based risk prediction model development for acute kidney injury in type 2 myocardial infarction patients.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute kidney injury (AKI) following acute myocardial infarction (AMI) notably affects patient outcomes. The impact of KDIGO AKI staging on post-discharge short- and long-term outcomes, particularly early-stage AKI, is not well understood. This study evaluates the prognostic implications of various KDIGO stages in AMI patients. Methods: Utilizing the Medical Information Mart for Intensive Care IV (version 3.0) database, this retrospective cohort study included adult patients primarily diagnosed with AMI. Statistical analyses, including doubly robust estimation, propensity score matching, logistic regression, and Cox regression, were performed. The study compared Non-AKI (KDIGO stage 0) with Mild-AKI (maximum KDIGO stage 1 during hospitalization), and Normal-or-mild AKI (KDIGO stages 0-1) with Moderate-to-severe AKI (KDIGO stages 2-3). Results: Among 5,715 patients analyzed, 4,306 (75.36%) developed AKI. Doubly robust analysis revealed no significant differences in outcomes between Non-AKI and Mild-AKI groups (28-day mortality: OR 0.97, 95% CI 0.68-1.38; 180-day mortality: HR 0.94, 95% CI 0.76-1.18; 1-year mortality: HR 0.98, 95% CI 0.81-1.20). However, Moderate-to-severe AKI was significantly associated with worse outcomes compared to Normal-or-mild AKI (28-day mortality: OR 1.67, 95% CI 1.36-2.05; 180-day mortality: HR 1.06, 95% CI 1.02-1.10; 1-year mortality: HR 1.22, 95% CI 1.07-1.38; all Conclusions: Patients with Mild-AKI can be considered as having "subclinical AKI," with prognoses similar to Non-AKI patients. In contrast, Moderate-to-severe AKI significantly worsens prognosis compared to Normal-or-mild AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.